| Vascular Protective Effects of Diabetes Medications that Mimic or Increase Glucagon-Like Peptide-1 Activity. | |
| | |
MedLine Citation:
|
PMID: 22280335 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The incidence of type 2 diabetes (T2DM) is increasing rapidly worldwide and is a strong risk factor for cardiovascular disease (CVD) events. Although hyperglycemia is associated with increased CVD, intensive glycemic control with current diabetes medications has failed in recent large clinical trials to reduce macrovascular disease, demonstrating that intensive glucose control alone is insufficient to reduce major CVD events. A new approach to lowering glucose takes advantage of the incretin system and medications that raise or mimic glucagon-like peptide-1 (GLP-1). These agents not only improve glycemic control by mechanisms that minimize hypoglycemia, but also improve lipoprotein profiles, blood pressure control and weight loss. There is also an increasing evidence that at least pharmacologic concentrations of GLP-1 or GLP-1 mimetics may improve endothelial function and have direct vascular-protective effects. Importantly, these benefits transpired even before the improvements in weight and overall glucose control occurred. It remains to be seen whether the chronic effects of GLP-1 activity on glucose, CVD risk factors and vascular function will lead to lasting beneficial effects on CVD risk. If preliminary findings on the vasculoprotective effects of GLP-1 agents are validated and confirmed in longitudinal clinical trials, this class of drugs may represent a paradigm shift in the treatment of vascular disease in both patients with diabetes and in non-diabetic individuals at high risk for CVD. Recent patents regarding GLP-1 agents are discussed in this review article. |
| | |
Authors:
|
Angelica J Motta; Juraj Koska; Peter Reaven; Raymond Q Migrino |
Related Documents
:
|
8772575 - Circulating factors and insulin resistance. ii. the action of the novel myo-inositol cy... 10214935 - Kup is the major k+ uptake system in escherichia coli upon hyper-osmotic stress at a lo... 15277525 - The transcription factor ccaat/enhancer-binding protein alpha is required for the intra... 19686715 - Dual action of phenylarsine oxide on the glucose transport activity of glut1. 2171925 - The stress response to anaesthesia in ponies: barbiturate anaesthesia. 17478005 - Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging f... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-26 |
Journal Detail:
|
Title: Recent patents on cardiovascular drug discovery Volume: - ISSN: 2212-3962 ISO Abbreviation: Recent Pat Cardiovasc Drug Discov Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-27 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101263805 Medline TA: Recent Pat Cardiovasc Drug Discov Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Phoenix Veterans Affairs Health Care System, 650 E. Indian School Road, Phoenix AZ 85012, USA. Raymond.Migrino@va.gov. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Combining Stem Cells and Tissue Engineering in Cardiovascular Repair - a Step Forward to Derivation ...
Next Document: Endothelial Dysfunction and Atherosclerosis: Focus on Novel Therapeutic Approaches.